Literature DB >> 15820074

[Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer].

Guo Wei1, Guo-En Fang, Jian-Wei Bi, Xiao-Jun Shen, Ming-Ming Nie, Xu-Chao Xue, Ji-De Hua.   

Abstract

BACKGROUND &
OBJECTIVE: Abdominal recurrence from exfoliated cancer cells contributes a lot to treatment failure of advanced gastric cancer. Intraperitoneal chemotherapy, which has been proved effective in eliminating exfoliated cancer cells in abdominal cavity, is a hot topic on treatment of gastric cancer. This study was to explore application of combined therapy of intraoperative hypotonic peritoneal chemo-hyperthermia and early postoperative intraperitoneal chemotherapy to gastric cancer.
METHODS: A total of 156 gastric cancer patients were randomized into 3 groups, and underwent the combined therapy (treatment group 1), intraoperative chemotherapy (treatment group 2), and peritoneal lavage with distilled water (control group), respectively.
RESULTS: The 2-year survival rate of treatment group 1 was significantly higher than that of control group (88.4% vs. 65.2%, P < 0.05). The 3-year survival rate of treatment group 1 was significantly higher than those of treatment group 2, and control group (71.1% vs. 50.0%, and 45.6%, P < 0.05). Occurrence of liver metastasis was significantly lower in treatment groups 1 and 2 than in control group (7.7%, and 10.2% vs. 27.3%, P < 0.05).
CONCLUSIONS: Combined therapy of intraoperative hypotonic chemo-hyperthermia and early postoperative intraperitoneal chemotherapy is effective for gastric cancer. Intraperitoneal chemotherapy can be used to prevent postoperative liver metastasis of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820074

Source DB:  PubMed          Journal:  Ai Zheng


  6 in total

Review 1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement.

Authors:  Maneesh K Beeharry; Wen-Tao Liu; Xue-Xin Yao; Min Yan; Zheng-Gang Zhu
Journal:  Transl Gastroenterol Hepatol       Date:  2016-10-20

3.  Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in Mainland China.

Authors:  Tao Suo; Haile Mahteme; Xin-Yu Qin
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

4.  Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinosis from advanced gastric cancer-effects on overall and disease free survival.

Authors:  Federico Coccolini; Andrea Celotti; Marco Ceresoli; Giulia Montori; Michele Marini; Fausto Catena; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2016-08

5.  Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: a cumulative meta-analysis of randomized controlled trials.

Authors:  Zheng He; Ting-Ting Zhao; Hui-Mian Xu; Zhen-Ning Wang; Ying-Ying Xu; Yong-Xi Song; Zhong-Ran Ni; Hao Xu; Song-Cheng Yin; Xing-Yu Liu; Zhi-Feng Miao
Journal:  Oncotarget       Date:  2017-09-11

6.  Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials.

Authors:  Jingxu Sun; Yongxi Song; Zhenning Wang; Peng Gao; Xiaowan Chen; Yingying Xu; Jiwang Liang; Huimian Xu
Journal:  BMC Cancer       Date:  2012-11-16       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.